Asia Pacific Monoclonal Antibody Therapeutics Market to expand at Impressive CAGR during Forecast Period: Transparency Market Research

The report provides detailed analysis of the current and emerging trends in the global monoclonal antibody therapeutics market. The market size according to application, source, end users and geography is provided in the report. Geographically, the market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Increasing incidence of diseases such cancer and other which affect the immune system of the body and also the therapeutic advantage of monoclonal antibody over conventional therapy are the major drivers for the growth of monoclonal antibody therapeutics market.

According to the report, the Monoclonal Antibody Therapeutics Market is projected to reach US$ 245,873.9 Mn in 2024 at a CAGR of 12.6% from 2015 to 2024.

North America dominated the monoclonal antibody therapeutics market in 2015, firstly due to presence of strong players in the region and secondly due to well established healthcare infrastructure facilities. In North America, autoimmune diseases segment has the maximum market share in terms on revenue, followed by cancer which is the second largest segment contributing for the total revenue of North America monoclonal antibody therapeutics market. Both these segments are expected to be the highest contributor for the growth of North America monoclonal antibody therapeutics market over the forecast period. As reported by American Cancer Society there are approximately, 1,685,210 new cancer cases detected in 2016 which is considered to be the important driver for the growth of the cancer segment. Also continuous investment in development of novel monoclonal antibodies in treating various autoimmune diseases, hematological diseases are expected to drive the market. Moreover the string reimbursement policy in U.S. enables treatment with monoclonal antibody accessible and affordable.

Europe was the second largest market for monoclonal antibody therapeutics in 2015 due to well-developed healthcare infrastructure facilities and awareness regarding usage of monoclonal antibodies in the treatment for diseases such as cancer and other autoimmune diseases. In Europe, according to application, the cancer and autoimmune disease segments are the most attractive segments. By source, human and humanized monoclonal antibody segments contribute highest in terms of revenue in the total monoclonal antibody therapeutics market. Due to well established healthcare system in Europe, the maximum share is acquired by hospitals in terms of revenue in the end users segment. Moreover, strategic mergers and acquisitions of big pharma companies with the small companies and increasing investment in research and development of novel monoclonal antibodies in treating various diseases is expected to drive the monoclonal antibody therapeutics market  throughout the forecast period.

Asia Pacific is expected to expand at a high CAGR during the forecast period from 2016 to 2024. Large patient pool and rising awareness about treatment option with monoclonal antibody in the region are the key growth factor of the monoclonal antibody therapeutics market. The booming medical tourism driven by rising government support and incorporation of different schemes by government to avail better treatment for patients is also expected to propel the market in the region. Increase in the number of mergers of key international players with Indian biopharmaceutical and biotechnology companies along with strengthening of supply chain in Asia Pacific owing to growing economy is expected to boost the growth of the market. India and China are expected to grow at highest CAGR during the forecast period due to increasing healthcare facilities, increase in the disposable income and increasing number of diseases. China market is expected to grow more in biosimilars due to emergence of many national players in the manufacturing of monoclonal antibodies.

Download Exclusive Sample Copy of Report – http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=18209

Latin America is expected to grow at a moderate CAGR due to slow economic development, as cost is the major restraining factor when it comes to treatment with monoclonal antibodies. Brazil dominated the monoclonal antibody therapeutics market in Latin America in 2015 and will be the focus area for market players due to large investments by government in health care infrastructure. Rising awareness about diagnosis of serious conditions and treatment with monoclonal antibodies due to its advantages over conventional therapies is anticipated to drive the monoclonal antibody therapeutics market in the region.

Middle East & Africa accounts for very low share of the global monoclonal antibody therapeutics market due to low availability of treatment options and lesser awareness among the people. However, global players have been entering Middle East & Africa through various distribution agreements to enhance the reach of their products and to establish their foothold in the region.

Major players operating in the monoclonal antibody therapeutics market are Bayer AG, F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, GlaxoSmithKline Plc., Merck & Co., Inc., Novartis AG, AbbVie Inc., Amgen Inc., Johnson & Johnson, Bristol – Myers Squibb Company, Biogen Inc. and others. The market is characterized by significant acquisitions, which has led to market consolidation, increasing the dominance of few the key players in the market.

 The monoclonal antibody therapeutics market has been segmented as follows:

Monoclonal antibody Therapeutics Market, by Application

  • Cancer
  • Autoimmune diseases
  • Infection
  • Hematological diseases
  • Ophthalmological diseases
  • Others (cardiovascular, transplant, respiratory and orthopedic)

Monoclonal antibody Therapeutics Market, by Source

  • Human
  • Humanized
  • Chimeric
  • Others (peptide antibody, murine antibody and rat – mouse antibody)

Monoclonal antibody Therapeutics Market, by End Users

  • Hospitals
  • Private clinics
  • Research institute

 Monoclonal antibody Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • U.K.
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • China
    • Australia
    • New Zealand
    • Rest of Asia Pacific
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • A.E.
    • Rest of MEA

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: 
sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

VN:F [1.9.22_1171]
Rating: 0.0/5 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)

No comments.

Leave a Reply

You must be logged in to post a comment.